Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

@article{Manns2001PeginterferonAP,
  title={Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial},
  author={Michael P. Manns and John McHutchison and Stuart C. Gordon and Vinod K. Rustgi and Mitchell L. Shiffman and Robert W. Reindollar and Zach Goodman and Kenneth J. Koury and Mei Ling and Janice K. Albrecht},
  journal={The Lancet},
  year={2001},
  volume={358},
  pages={958-965}
}

Figures and Tables from this paper

Peginterferon alfa-2a plus ribavirin is more effective than peginterferon alfa-2b plus ribavirin for treating chronic hepatitis C virus infection.

In patients with chronic HCV infection, peginterferon alfa-2a plus ribavirin produced a significantly higher sustained virological response (SVR) rate than pegin terferonAlfa- 2b plus Ribavirin.

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.

In patients with chronic hepatitis C, once-weekly peginterferon alfa-2a plus ribavirin was tolerated as well as interferonAlfa- 2b plus Ribavirin and produced significant improvements in the rate of sustained virologic response, as compared with interfer on alfa -2b plus ribvirin or pegin terferonalfa-3a alone.

Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons.

The marked discrepancy in the rates of sustained virologic response between HCV genotypes indicates that strategies are needed to improve the outcome in persons infected withHCV genotype 1.

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV/HCV co-infected patients

PEG-INF +RBV was significantly more effective than INF + RBV for the treatment of chronic hepatitis C in HIV co-infected patients, mainly of genotype 1 or 4.

Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients.

Among patients infected with both HIV and HCV, the combination of peginterferon alfa-2a plus ribavirin was significantly more effective than either interferonalfa- 2a plus Ribavirin or pegin terferonAlfa-3a monotherapy.

Peginterferon alfa-2a (40KD) plus ribavirin in chronic hepatitis C patients who failed previous interferon therapy

These results in a large patient cohort demonstrate that it is possible to cure a proportion of previous non-responders and relapsers by retreating with peginterferon alfa-2a (40KD) plus ribavirin.

Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3.

Treatment with peginterferon and ribavirin for 16 weeks in patients infected with HCV genotype 2 or 3 results in a lower overall sustained virologic response rate than treatment with the standard 24-week regimen.
...

References

SHOWING 1-10 OF 32 REFERENCES

Peginterferon alfa-2a in patients with chronic hepatitis C.

In patients with chronic hepatitis C, a regimen of peginterferon alfa-2a given once weekly is more effective than a regimen that has sustained absorption, a slower rate of clearance, and a longer half-life than unmodified interferonAlfa- 2a.

PEGINTERFERON ALFA-2 a IN PATIENTS WITH CHRONIC HEPATITIS C AND CIRRHOSIS

In patients with chronic hepatitis C and cirrhosis or bridging fibrosis, 180 μg of peginterferon alfa-2a administered once weekly is significantly more effective than 3 million units of standard interferonAlfa- 2a administered three times weekly.

A Dose‐Ranging Study of Pegylated Interferon Alfa‐2b and Ribavirin in Chronic Hepatitis C

Combined PEG‐Intron/ribavirin showed dose‐related synergistic anti‐HCV effects, which were numerically superior to those obtained with PEG-Intron monotherapy.

Prediction of response during interferon alfa 2b therapy in chronic hepatitis C patients using viral and biochemical characteristics: A comparison

Results indicate that testing for HCV RNA at week 12 to identify nonresponders and then discontinuing their treatment is practical, cost‐efficient and beneficial both to patients and to third‐party payers.

A randomized, double‐blind trial comparing pegylated interferon alfa‐2b to interferon alfa‐2b as initial treatment for chronic hepatitis C

PegIntron alfa‐2b maintained the clinical efficacy of interferon alfa'2b while preserving its safety profile and increased virologic response rates after treatment and after follow‐up, as compared with interferons alfa'; however, the higher rate of virolic response during treatment with 1.5 μg/kg peginterferonAlfa‐ 2b in patients infected with genotype 1 and high viral levels warrants further evaluation.

Discordance between serum alanine aminotransferase (ALT) and virologic response to IFN-alpha2b in chronic hepatitis C patients with high and low pretreatment serum hepatitis C virus RNA titers.

The results indicate that chronic HCV patients with high pretreatment HCV RNA titers showed greater discordance between sustained ALT andHCV RNA responses compared with patients with low pret treatment HCVRNA titers and that measurement of HCVs RNA should be included in the assessment of response to IFN therapy in chronic hepatitis C patients.

Liver transplantation for chronic viral hepatitis.

Liver transplantation for chronic viral hepatitis.

Liver transplantation remains a problem for end stage liver disease due to chronic viral hepatitis in contrast to the success with fulminant hepatitis B, D and C in which recurrence of viraemia is relatively rare, and there are no firm recommendations that can be given to prevent recurrence.